Can-Fite Biopharma, an Israeli company, has reached agreement with the US Food and Drug Administration (FDA) on the structure for a new Phase II/III clinical trial of CF101, the company’s lead anti-inflammatory compound. According to this news item: “The new trial, which will begin in a few months, will include 300 patients in Israel, Europe, and the US.”
You can read more on CF101 here.
Category: Psoriasis Research
Tags: adenosine, Can-Fite, CF101
